Selective Inhibiton of Nuclear Export (SINE)

Overview

Selective Inhibition of Nuclear Export (SINE) is a new treatment classification that can block the export of TSPs (tumor suppressor proteins) and GRPs (growth regulatory proteins) from leaving the myeloma cell. This allows these cancer fighting proteins to remain in the center of the cell (nucleus) to better fight cancer.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Selinexor
Selinexor

Selinexor belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

SparkCures Verified Accurate, up-to-date information. Learn more

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Selinexor
Selinexor

Selinexor belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Selinexor
Selinexor

Selinexor belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

SparkCures Verified Accurate, up-to-date information. Learn more

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

Resources

There are no resources, links or videos to display for this tag.